

AKEBIA THERAPEUTICS INC.

COLORADO DISCLOSURE INFORMATION

I. PURPOSE

On May 16, 2019, Colorado Governor Jared S. Polis approved House Bill 19-1131, legislation that requires pharmaceutical manufacturers, like Akebia Therapeutics, Inc. (Akebia), to disclose certain information to Prescribers in the course of conducting business. Specifically, this information includes:

- The Wholesale Acquisition Cost of prescription drugs manufactured, and,
- The names of at least three generic prescription drugs from the same therapeutic class (as the drug above).

This information is to be provided in writing to all Prescribers licensed in the state of Colorado, that Akebia conducts business with.

II. WHOLESALE ACQUISITION COST

PRODUCT NAME	MANUFACTURER	NDC	PKG SIZE
Vafseo® (Vadadustat) 150mg	Akebia Therapeutics, Inc.	59922-0641-60	60
		WAC / PACK	\$1,278.00
		WAC / TAB	\$21.30
Vafseo® (Vadadustat) 300mg	Akebia Therapeutics, Inc.	59922-0642-60	60
		WAC / PACK	\$2,556.00
		WAC / TAB	\$42.60

III. GENERIC ALTERNATIVES

GENERIC PRODUCTS ¹
There are no generic prescription drugs in the same therapeutic class as the drug above

² AKEBIA IS NOT AFFILIATED WITH THE MANUFACTURERS OF ANY PRODUCTS LISTED, NOR DOES IT MANUFACTURE, ENDORSE, OR OTHERWISE RECOMMEND THE USE OR PRESCRIPTION OF THESE PRODUCTS. THIS INFORMATION IS BEING PROVIDED PURSUANT TO THE REQUIREMENTS SET FORTH BY COLORADO HOUSE BILL 19-1131, AND 19-1172, CODIFIED AT CO REV. STAT. §12-280-308, AND CO REV. STAT. §12-42.5-308.